Eleventh SOHO Annual Meeting
The Eleventh Society of Hematologic Oncology Annual Meeting was held September 6-9, 2023, in Houston, Texas. The meeting featured presentations and sessions that focused on the latest advances in the field of hematologic oncology.
Advertisement
Advertisement
The meeting had more than 2,500 registrants attending in person or online.
The award was created in honor of Michael J. Keating, MD, a founding member and past president of SOHO.
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
All patients included in the study required treatment and had not previously received psychiatric treatment.
The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial.
The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option.
Noteworthy regional disparities were noticed in treatment strategies.
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Patients with MPNs faced higher direct and indirect costs and were significantly more likely to take disability leave.
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Researchers presented data from the randomized withdrawal phase of the study at the SOHO Annual Meeting.
Brexucabtagene autoleucel is a promising therapy in relapsed or refractory MCL.
Pirtobrutinib can be safely used along with concomitant antithrombotic therapy (CAT) in treating B-cell malignancies.
The overall response rate was 83.8% and the CR rate was 73% after the median follow-up of eight months.
A first-line induction regimen that alternates VR-CAP with R-DHAP can improve treatment response in newly diagnosed MCL.
The patient cohort had median OS of 27 months and a five-year OS of 24.5%.
The award recognizes a SOHO member who has significantly contributed to the advancement of blood cancer care and research.
Multiple posters received awards from the Society during a ceremony held at the annual meeting.
SOHO President Jennifer Brown, MD, PhD, talks about why she chose personalized medicine as this year's theme.
The Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO) began on Wednesday.
The meeting will be held September 6-9, 2023, in Houston, Texas.
The bispecific antibody mosunetuzumab in relapsed or refractory follicular lymphoma continues to show durable responses.
